Zalups R K, Cherian M G, Barfuss D W
Division of Basic Medical Sciences, Mercer University School of Medicine, Macon, GA 31207.
Toxicology. 1993 Oct 25;83(1-3):61-78. doi: 10.1016/0300-483x(93)90092-7.
In the present study, we evaluated the renal and hepatic accumulation of mercury, the intrarenal distribution of mercury and the urinary and fecal excretion of mercury in rats injected intravenously with a non-toxic 0.1 mumol/kg-dose of mercury in the form of mercuric chloride (HgCl2) or a complex of mercury-metallothionein (Hg-MT). Between 6 and 72 h after injection, the concentration of mercury in the kidneys of the rats injected with Hg-MT was significantly greater than that in the rats injected with HgCl2. The greatest difference in the renal concentration of mercury between the two groups of rats was detected 6 h after injection. In the kidneys of both experimental groups of rats, the cortex and the outer stripe of the outer medulla contained the highest concentrations of mercury, with the greatest concentrations found in the renal cortex and outer stripe of the outer medulla of the rats injected with Hg-MT. No differences were found between the two experimental groups with respect to the concentration of mercury in the renal inner stripe of the outer medulla and inner medulla throughout 72 h of study. The content of mercury in the blood and liver decreased over time in both groups of rats, but was always significantly greater in the blood and liver of rats injected with HgCl2. The rats injected with Hg-MT excreted more than eight times the amount of mercury in the urine than the corresponding rats injected with HgCl2 during 72 h. These data indicate that there may be decreased tubular reabsorption of filtered Hg-MT and/or tubular secretion of mercury in the rats injected with Hg-MT. In contrast, the rats injected with HgCl2 excreted significantly more mercury in the feces during the same period of time than the corresponding rats injected with Hg-MT. In conclusion, our data clearly indicate that the renal and hepatic uptake and accumulation of mercury, and the urinary and fecal excretion of mercury, are altered significantly when inorganic mercury is administered intravenously as a complex with metallothionein.
在本研究中，我们评估了静脉注射无毒剂量（0.1 μmol/kg）氯化汞（HgCl₂）形式的汞或汞 - 金属硫蛋白复合物（Hg - MT）的大鼠体内汞在肾脏和肝脏中的蓄积情况、肾脏内汞的分布以及汞的尿排泄和粪排泄。注射后6至72小时内，注射Hg - MT的大鼠肾脏中汞的浓度显著高于注射HgCl₂的大鼠。两组大鼠肾脏汞浓度的最大差异在注射后6小时检测到。在两组实验大鼠的肾脏中，皮质和外髓质的外带汞浓度最高，注射Hg - MT的大鼠肾脏皮质和外髓质外带中的汞浓度最高。在整个72小时的研究中，两组实验大鼠在外髓质内带和内髓质中的汞浓度没有差异。两组大鼠血液和肝脏中的汞含量均随时间下降，但注射HgCl₂的大鼠血液和肝脏中的汞含量始终显著更高。在72小时内，注射Hg - MT的大鼠尿中汞的排泄量是注射相应剂量HgCl₂大鼠的八倍多。这些数据表明，注射Hg - MT的大鼠中滤过的Hg - MT的肾小管重吸收和/或汞的肾小管分泌可能减少。相反，在同一时间段内，注射HgCl₂的大鼠粪便中排泄的汞比注射相应剂量Hg - MT的大鼠显著更多。总之，我们的数据清楚地表明，当无机汞与金属硫蛋白形成复合物静脉给药时，汞在肾脏和肝脏中的摄取和蓄积以及汞的尿排泄和粪排泄会发生显著改变。
